Nasus Pharma
- Country
- Ownership
- -
- Employees
- -
- Market Cap
- -
- Introduction
Nasus Pharma Ltd. engages in the development of intranasal drugs for emergency medical conditions. It offers Powder-Based Intranasal (PBI) specialized product portfolio, to address acute medical conditions and public health threats. The company was founded by Udi Gilboa and Dalia Megiddo in May 2019 and is headquartered in Tel Aviv, Israel.
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Comparative PK/PD of FMXIN002 and EpiPen, in Healthy Adults With Allergic Rhinitis
- Conditions
- AnaphylaxisAllergy
- Interventions
- Drug: FMXIN002 single doseDrug: Epinephrine autoinjector single doseDrug: FMXIN002 single dose + NACDrug: Epinephrine autoinjector double doseDrug: FMXIN002 double doseDrug: FMXIN002 double dose + NAC
- First Posted Date
- 2025-11-14
- Last Posted Date
- 2025-11-14
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 50
- Registration Number
- NCT07228325
- Locations
- 🇨🇦
Pharma Medica Research Inc, Mississauga, Canada
FMXIN002 in Patients at Risk of Anaphylaxis
- Conditions
- Anaphylaxis Food
- First Posted Date
- 2025-07-01
- Last Posted Date
- 2025-07-01
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT07045701
- Locations
- 🇮🇱
Shamir Medical Center, Be'er Ya'aqov, Israel
Comparative Bioavailability of Intranasal Epinephrine
- Conditions
- Anaphylactic ReactionAnaphylaxis
- First Posted Date
- 2024-01-12
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 12
- Registration Number
- NCT06205134
- Locations
- 🇮🇱
Clinical Pharmacology Unit, Hadassah Medical Center, Ein Karem, Jerusalem, Israel
COVID-19 Prevention Trial: Effect of Prophylactic Use of TAFFIXâ„¢ on Infection Rate by SARS-CoV-2 Virus (COVID-19).
- Conditions
- Upper Respiratory Tract InfectionsCOVID-19
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 693
- Registration Number
- NCT05252468
- Locations
- 🇧🇬
Diagnostics and Consultation Center Convex Ltd, Sofia, Bulgaria
A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder
- Conditions
- Opioid Overdose
- First Posted Date
- 2021-01-19
- Last Posted Date
- 2022-05-02
- Lead Sponsor
- Nasus Pharma
- Target Recruit Count
- 46
- Registration Number
- NCT04713709
- Locations
- 🇨🇦
Pharma Medica Research Inc, Mississauga, Ontario, Canada
- Prev
- 1
- 2
- Next
News
Nasus Pharma Partners with Aptar to Accelerate NS002 Intranasal Epinephrine Development
Nasus Pharma has executed comprehensive agreements with Aptar, a leading global drug delivery systems manufacturer, to support NS002's clinical development and commercialization pathway.